Northern Trust’s Xenon Pharmaceuticals XENE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $40.5M | Buy |
671,566
+143,783
| +27% | +$7.98M | ﹤0.01% | 1342 |
|
|
2026
Q1 | $30.7M | Buy |
527,783
+89,069
| +20% | +$4.1M | ﹤0.01% | 1421 |
|
|
2025
Q4 | $19.7M | Sell |
438,714
-59,433
| -12% | -$2.5M | ﹤0.01% | 1664 |
|
|
2025
Q3 | $20M | Buy |
498,147
+8,207
| +2% | +$289K | ﹤0.01% | 1682 |
|
|
2025
Q2 | $15.3M | Buy |
489,940
+408,916
| +505% | +$13.3M | ﹤0.01% | 1818 |
|
|
2025
Q1 | $2.72M | Buy |
81,024
+15,241
| +23% | +$579K | ﹤0.01% | 2756 |
|
|
2024
Q4 | $2.58M | Buy |
65,783
+22,377
| +52% | +$925K | ﹤0.01% | 2878 |
|
|
2024
Q3 | $1.71M | Sell |
43,406
-3,446
| -7% | -$139K | ﹤0.01% | 3095 |
|
|
2024
Q2 | $1.83M | Sell |
46,852
-1,618
| -3% | -$64.7K | ﹤0.01% | 2943 |
|
|
2024
Q1 | $2.09M | Sell |
48,470
-13,501
| -22% | -$621K | ﹤0.01% | 2932 |
|
|
2023
Q4 | $2.85M | Sell |
61,971
-7,196
| -10% | -$254K | ﹤0.01% | 2804 |
|
|
2023
Q3 | $2.36M | Buy |
69,167
+3,684
| +6% | +$138K | ﹤0.01% | 2848 |
|
|
2023
Q2 | $2.52M | Buy |
65,483
+4,480
| +7% | +$178K | ﹤0.01% | 2877 |
|
|
2023
Q1 | $2.18M | Buy |
61,003
+786
| +1% | +$29K | ﹤0.01% | 2902 |
|
|
2022
Q4 | $2.37M | Buy |
60,217
+9,326
| +18% | +$340K | ﹤0.01% | 2906 |
|
|
2022
Q3 | $1.84M | Buy |
50,891
+2,895
| +6% | +$104K | ﹤0.01% | 3050 |
|
|
2022
Q2 | $1.46M | Buy |
47,996
+3,220
| +7% | +$97.4K | ﹤0.01% | 3219 |
|
|
2022
Q1 | $1.37M | Sell |
44,776
-5,820
| -12% | -$174K | ﹤0.01% | 3278 |
|
|
2021
Q4 | $1.58M | Buy |
50,596
+12,746
| +34% | +$381K | ﹤0.01% | 3339 |
|
|
2021
Q3 | $579K | Sell |
37,850
-6,871
| -15% | -$119K | ﹤0.01% | 3717 |
|
|
2021
Q2 | $832K | Sell |
44,721
-5,841
| -12% | -$108K | ﹤0.01% | 3575 |
|
|
2021
Q1 | $904K | Buy |
50,562
+3,940
| +8% | +$66.8K | ﹤0.01% | 3624 |
|
|
2020
Q4 | $717K | Sell |
46,622
-15,731
| -25% | -$184K | ﹤0.01% | 3627 |
|
|
2020
Q3 | $690K | Buy |
62,353
+718
| +1% | +$8.45K | ﹤0.01% | 3528 |
|
|
2020
Q2 | $772K | Buy |
61,635
+3,036
| +5% | +$38.6K | ﹤0.01% | 3435 |
|
|
2020
Q1 | $664K | Buy |
58,599
+14,456
| +33% | +$206K | ﹤0.01% | 3371 |
|
|
2019
Q4 | $579K | Buy |
44,143
+6,507
| +17% | +$68.4K | ﹤0.01% | 3523 |
|
|
2019
Q3 | $339K | Hold |
37,636
| – | – | ﹤0.01% | 3632 |
|
|
2019
Q2 | $371K | Buy |
37,636
+13,434
| +56% | +$129K | ﹤0.01% | 3637 |
|
|
2019
Q1 | $246K | Buy |
24,202
+11,956
| +98% | +$101K | ﹤0.01% | 3723 |
|
|
2018
Q4 | $77K | Buy |
12,246
+1,948
| +19% | +$17.3K | ﹤0.01% | 3973 |
|
|
2018
Q3 | $136K | Buy |
+10,298
| New | +$119K | ﹤0.01% | 3961 |
|
Other funds holding XENE
ACA
PCH
DCM
JT
Northern Trust's XENE Position: Q2 2026 in Review
Northern Trust increased its Xenon Pharmaceuticals (XENE) stake by 27% in Q2 2026, buying an estimated $7.98M and bringing the position to 671,566 shares worth $40.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1342.
Northern Trust first reported a position in XENE in Q3 2018 and has held it in 32 quarters since. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.
- Northern Trust held 671,566 shares of Xenon Pharmaceuticals worth $40.5M as of Q2 2026.
- Northern Trust bought 143,783 Xenon Pharmaceuticals shares in Q2 2026, an estimated $7.98M.
- Xenon Pharmaceuticals made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #1342 holding.
- Northern Trust first reported a position in Xenon Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
- 316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.
Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.